CRISPR/Cas9 gene editing: New hope for Alzheimer's disease therapeutics

Simple item page
dc.contributorAalto-yliopistofi
dc.contributorAalto Universityen
dc.contributor.authorBhardwaj, Shanuen_US
dc.contributor.authorKesari, Kavindra Kumaren_US
dc.contributor.authorRachamalla, Maheshen_US
dc.contributor.authorMani, Shalinien_US
dc.contributor.authorAshraf, Ghulam Mden_US
dc.contributor.authorJha, Saurabh Kumaren_US
dc.contributor.authorKumar, Praviren_US
dc.contributor.authorAmbasta, Rashmi K.en_US
dc.contributor.authorDureja, Harishen_US
dc.contributor.authorDevkota, Hari Prasaden_US
dc.contributor.authorGupta, Gauraven_US
dc.contributor.authorChellappan, Dinesh Kumaren_US
dc.contributor.authorSingh, Sachin Kumaren_US
dc.contributor.authorDua, Kamalen_US
dc.contributor.authorRuokolainen, Janneen_US
dc.contributor.authorKamal, Mohammad Amjaden_US
dc.contributor.authorOjha, Shreeshen_US
dc.contributor.authorJha, Niraj Kumaren_US
dc.contributor.departmentDepartment of Applied Physicsen
dc.contributor.groupauthorWood Chemistryen
dc.contributor.groupauthorMolecular Materialsen
dc.contributor.organizationDelhi Technological Universityen_US
dc.contributor.organizationUniversity of Saskatchewanen_US
dc.contributor.organizationJaypee University of Information Technologyen_US
dc.contributor.organizationKing Abdulaziz Universityen_US
dc.contributor.organizationSharda Universityen_US
dc.contributor.organizationMaharshi Dayanand Universityen_US
dc.contributor.organizationKumamoto Universityen_US
dc.contributor.organizationSuresh Gyan Vihar Universityen_US
dc.contributor.organizationInternational Medical Universityen_US
dc.contributor.organizationLovely Professional Universityen_US
dc.contributor.organizationUniversity of Technology Sydneyen_US
dc.contributor.organizationSichuan Universityen_US
dc.contributor.organizationUnited Arab Emirates Universityen_US
dc.date.accessioned2021-08-25T06:51:22Z
dc.date.available2021-08-25T06:51:22Z
dc.date.issued2022-09en_US
dc.descriptionPublisher Copyright: © 2021
dc.description.abstractBackground: Alzheimer's disease (AD) is an insidious, irreversible, and progressive neurodegenerative health condition manifesting as cognitive deficits and amyloid beta (Aβ) plaques and neurofibrillary tangles. Approximately 50 million individuals are affected by AD, and the number is rapidly increasing globally. This review explores the role of CRISPR/Cas9 gene editing in the management of AD and its clinical manifestations. Aim of Review: This review aims to provide a deep insight into the recent progress in CRISPR/Cas9-mediated genome editing and its use against neurodegenerative disorders, specifically AD. However, we have referred to its use against parkinsons's disease (PD), Huntington's disease (HD), and other human diseases, as is one of the most promising and emerging technologies for disease treatment. Key Scientific Concepts of Review: The pathophysiology of AD is known to be linked with gene mutations, that is, presenilin (PSEN) and amyloid beta precursor protein (APP). However, clinical trials focused at the genetic level could not meet the desired efficiency. The CRISPR/Cas9 genome editing tool is one of the most powerful technologies for correcting inconsistent genetic signatures and now extensively used for AD management. It has significant potential for the correction of undesired gene mutations associated with AD. This technology has allowed the development of empirical AD models, therapeutic lines, and diagnostic approaches for better understanding the nervous system, from in vitro to in vivo models.en
dc.description.versionPeer revieweden
dc.format.mimetypeapplication/pdfen_US
dc.identifier.citationBhardwaj, S, Kesari, K K, Rachamalla, M, Mani, S, Ashraf, G M, Jha, S K, Kumar, P, Ambasta, R K, Dureja, H, Devkota, H P, Gupta, G, Chellappan, D K, Singh, S K, Dua, K, Ruokolainen, J, Kamal, M A, Ojha, S & Jha, N K 2022, ' CRISPR/Cas9 gene editing : New hope for Alzheimer's disease therapeutics ', Journal of Advanced Research, vol. 40, pp. 207-221 . https://doi.org/10.1016/j.jare.2021.07.001en
dc.identifier.doi10.1016/j.jare.2021.07.001en_US
dc.identifier.issn2090-1232
dc.identifier.otherPURE UUID: 4054a01b-5122-495f-9f9c-eb834e8723feen_US
dc.identifier.otherPURE ITEMURL: https://research.aalto.fi/en/publications/4054a01b-5122-495f-9f9c-eb834e8723feen_US
dc.identifier.otherPURE LINK: http://www.scopus.com/inward/record.url?scp=85111514756&partnerID=8YFLogxKen_US
dc.identifier.otherPURE FILEURL: https://research.aalto.fi/files/117570968/SCI_Bhardwaj_etal_JARE_2022.pdfen_US
dc.identifier.urihttps://aaltodoc.aalto.fi/handle/123456789/109124
dc.identifier.urnURN:NBN:fi:aalto-202108258361
dc.language.isoenen
dc.publisherCairo University
dc.relation.ispartofseriesJournal of Advanced Researchen
dc.rightsopenAccessen
dc.subject.keywordAlzheimer's diseaseen_US
dc.subject.keywordAPPen_US
dc.subject.keywordCRISPR/Cas9en_US
dc.subject.keywordGene editingen_US
dc.subject.keywordNeurodegenerationen_US
dc.subject.keywordPresenilinen_US
dc.subject.keywordTherapeuticsen_US
dc.titleCRISPR/Cas9 gene editing: New hope for Alzheimer's disease therapeuticsen
dc.typeA1 Alkuperäisartikkeli tieteellisessä aikakauslehdessäfi
dc.type.versionpublishedVersion
Files
Collections
[article-cris] Perustieteiden korkeakoulu / SCI